WHO ICTRP trial
In-vivo Bioequivalence Study of Mefenamic acid 250 mg Capsules of The Test Drug…
IRCT20200105046010N148 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT20200105046010N148 |
|---|---|
| Public title | In-vivo Bioequivalence Study of Mefenamic acid 250 mg Capsules of The Test Drug (Alborz Darou, Iran) |
| Scientific title | In-vivo Bioequivalence Study of Mefenamic acid 250 mg Capsules of The Test Drug (Alborz Darou, Iran) in Compared with The Reference Drug (PONSTAN® 250 mg Caps., Pfizer, Swiss) In Iranian Healthy Volunteers |
| Primary sponsor | Alborzdarou pharmaceutical company |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | Bioequivalence |
| Countries | Iran (Islamic Republic of) |
| Conditions | This study is performed on healthy volunteers.. |
| Interventions | Intervention 1: Intervention group: Single-dose of Mefenamic acid 250 mg Capsules of The Test Drug (Alborz Darou, Iran) , in the first period. Cross-over design with one week washing period.After one week in the second period, a single dose… |
| Registration date | Aug 5, 2025 |
| Target size | 24 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: